Our top pick for
Matinas BioPharma Holdings, Inc is a biotechnology business based in the US. Matinas BioPharma shares (MTNB) are listed on the NYSE MKT and all prices are listed in US Dollars. Matinas BioPharma employs 20 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$0.66 - $2.22|
|50-day moving average||$1.07|
|200-day moving average||$1.12|
|Wall St. target price||$3.08|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.13|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||$-14,200,585|
|Return on assets TTM||-27.21%|
|Return on equity TTM||-46.39%|
|Market capitalisation||$179.8 million|
TTM: trailing 12 months
There are currently 15.8 million Matinas BioPharma shares held short by investors – that's known as Matinas BioPharma's "short interest". This figure is 2% up from 15.5 million last month.
There are a few different ways that this level of interest in shorting Matinas BioPharma shares can be evaluated.
Matinas BioPharma's "short interest ratio" (SIR) is the quantity of Matinas BioPharma shares currently shorted divided by the average quantity of Matinas BioPharma shares traded daily (recently around 1.9 million). Matinas BioPharma's SIR currently stands at 8.51. In other words for every 100,000 Matinas BioPharma shares traded daily on the market, roughly 8510 shares are currently held short.
However Matinas BioPharma's short interest can also be evaluated against the total number of Matinas BioPharma shares, or, against the total number of tradable Matinas BioPharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Matinas BioPharma's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Matinas BioPharma shares in existence, roughly 80 shares are currently held short) or 0.0806% of the tradable shares (for every 100,000 tradable Matinas BioPharma shares, roughly 81 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Matinas BioPharma.
Find out more about how you can short Matinas BioPharma stock.
We're not expecting Matinas BioPharma to pay a dividend over the next 12 months.
Over the last 12 months, Matinas BioPharma's shares have ranged in value from as little as $0.66 up to $2.22. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while Matinas BioPharma's is 2.6404. This would suggest that Matinas BioPharma's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Matinas BioPharma Holdings, Inc. , a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nano-crystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid formulation for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections.
Everything we know about the TC Bancshares IPO, plus information on how to buy in.
Everything we know about the Soulgate IPO, plus information on how to buy in.
Everything we know about the Alzamend Neuro IPO, plus information on how to buy in.
Everything we know about the Singular Genomics Systems IPO, plus information on how to buy in.
Everything we know about the Golden Sun Education Group Limited IPO, plus information on how to buy in.
Everything we know about the Phillips Edison & Company IPO, plus information on how to buy in.
Everything we know about the FIGS IPO, plus information on how to buy in.
Everything we know about the DLocal Limited IPO, plus information on how to buy in.
Everything we know about the Torchy’s Tacos IPO, plus information on how to buy in.
Everything we know about the Dutch Bros Coffee IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.